Anitha Anne

Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.

Cooley advised Turnstone Biologics, a clinical-stage biotechnology company, on its upsized $80 million initial public offering.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised AN2 Therapeutics on its $79 million initial public offering of 4,600,000 shares of common stock at a price to the public of $15.00 per share. AN2 is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Partner Josh Seidenfeld, associate Anitha Anne and Sally Kay of counsel led the Cooley team.

Cooley advised Lyell Immunopharma, a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, on its $425 million initial public offering of 25,000,000 shares of its common stock. Partners Dave Peinsipp, Charlie Kim, Chad Mills and Lauren Creel led the Cooley team advising Lyell on its public debut, which marks the third largest biotech IPO in history.